Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 1,601–1,700 of 4,628
Schmid, U., Liesenfeld, K., Fleury, A., Dallinger, C., & Freiwald, M. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3452-0 · Cited by 22
Anticancer drug treatment for advanced lung cancer with interstitial lung disease
Otsubo, K., Okamoto, I., Hamada, N., & Nakanishi, Y. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.03.002 · Cited by 22
C-proSP-B: A Possible Biomarker for Pulmonary Diseases?
Kahn, N. C., Rossler, A.-K., Hornemann, K., Muley, T., Grünig, E., Schmidt, W. W., Herth, F. J. F., & Kreuter, M. (2018) · Respiration · doi:10.1159/000488245 · Cited by 22
Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis
Fukunaga, K., Yokoe, S., Kawashima, S., et al. (2018) · Respirology Case Reports · doi:10.1002/rcr2.363 · Cited by 22
“Nintedanib is an intracellular inhibitor of tyrosine kinases that targets the fibroblast growth factor (FGF) receptor, vascular endothelial growth factor (VEGF) receptor, and platelet-derived growth factor (PDGF) receptor [2].”
BackgroundTherapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases
Ito, Y., Tazaki, G., Kondo, Y., Takahashi, G., & Sakamaki, F. (2019) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2019.02.021 · Cited by 23
Diagnosing complications and co-morbidities of fibrotic interstitial lung disease
Margaritopoulos, G. A., Kokosi, M. A., & Wells, A. U. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1632196 · Cited by 24
Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update
Wongkarnjana, A., Yanagihara, T., & Kolb, M. R. J. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1673733 · Cited by 25
Self-citationTackling MARCKS‐PIP3 circuit attenuates fibroblast activation and fibrosis progression
Yang, D. C. H., Li, J., Xu, J., Oldham, J. M., Phan, S. H., Last, J. A., Wu, R., & Chen, C. (2019) · The FASEB Journal · doi:10.1096/fj.201901705r · Cited by 28
“Additionally, the exact mechanism of action for pirfenidone is unknown, and these drugs also come with a plethora of detrimental side effects that necessitate stopping treatment in the affected patients (4, 7, 12, 13, 46).”
BackgroundGaldo, F. D., Hartley, C., & Allanore, Y. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30007-2 · Cited by 26
Smith, M. L., Hariri, L. P., Mino-Kenudson, M. A., Đačić, S., Attanoos, R. L., Borczuk, A., Colby, T. V., Cooper, W. A., Jones, K. D., Leslie, K. O., et al. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2020-0052-ra · Cited by 24
Singh, V., Singh, S., Sharma, B., Bairwa, M. L., Gothi, D., Desai, U. D., Joshi, J. M., Talwar, D., Singh, A., Dhar, R., et al. (2020) · Lung India · doi:10.4103/lungindia.lungindia_275_20 · Cited by 25
Self-citationAntibody-mediated depletion of CCR10+EphA3+ cells ameliorates fibrosis in IPF
Hohmann, M. S., Habiel, D. M., Espíndola, M. S., Huang, G., Jones, I. C., Narayanan, R., Coelho, A. L., Oldham, J. M., Noth, I., Ma, S., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.141061 · Cited by 23
Self-citationHuang, T., Kuo, C., Chen, C., Tseng, Y., Wu, C., & Lin, S. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01530-6 · Cited by 25
Aschner, Y., & Downey, G. P. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0049tr · Cited by 25
Jiang, H., Zhou, R., An, L., Guo, J., Hou, X., Tang, J., Wang, F., & Du, Q. (2023) · Scientific Reports · doi:10.1038/s41598-023-36944-1 · Cited by 24
Proteomic Biomarkers of Quantitative Interstitial Abnormalities in COPDGene and CARDIA Lung Study
Choi, B., Liu, G. Y., Sheng, Q., Amancherla, K. V., Perry, A., Huang, X., Estépar, R. S. J., Ash, S. Y., Guan, W., Jacobs, D. R., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202307-1129oc · Cited by 21
Highlights on Future Treatments of IPF: Clues and Pitfalls
Libra, A., Sciacca, E., Muscato, G., Sambataro, G., Spicuzza, L., & Vancheri, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158392 · Cited by 25
“Inhibitors targeting these kinases are currently explored as potential treatments to modulate aberrant signaling cascades and mitigate the fibrotic processes associated with IPF [57].”
BackgroundTu, M., Lu, C., Jia, H., Chen, S., Wang, Y., Li, J., Cheng, J., Yang, M., & Zhang, G. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05698-3 · Cited by 24
68Ga-Trivehexin: Current Status of αvβ6-Integrin Imaging and Perspectives
Urso, L., Napolitano, R., Speltri, G., Tuncel, M., Badrane, I., Uccelli, L., Porto, F., Martini, P., Niorettini, A., Cittanti, C., et al. (2025) · Cancers · doi:10.3390/cancers17091504 · Cited by 23
“Moreover, [ 68 Ga]Ga-Trivehexin PET/CT could potentially enable the assessment of the dynamic process of fibrosis, allowing visualization of the response to new treatments like Nintedanib [54].”
Hagmeyer, L., Treml, M., Priegnitz, C., & Randerath, W. J. (2016) · Respiration · doi:10.1159/000444690 · Cited by 22
New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis: only PROMises?
Wijsenbeek, M. S., van Manen, M. J. G., & Bonella, F. (2016) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000294 · Cited by 24
Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
Glassberg, M. K., Wijsenbeek, M. S., Gilberg, F., Petzinger, U., Kirchgaessler, K.-U., & Albera, C. (2019) · European Respiratory Journal · doi:10.1183/13993003.00399-2019 · Cited by 23
Derseh, H. B., Dewage, S. N. V., Perera, K. U. E., Pagel, C. N., Koumoundouros, E., Organ, L. A., & Snibson, K. J. (2019) · Scientific Reports · doi:10.1038/s41598-019-56412-z · Cited by 21
Familial Interstitial Lung Disease
Kropski, J. A. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0040-1708054 · Cited by 23
Nonspecific Interstitial Pneumonia
Teoh, A. K. Y., & Corte, T. J. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0040-1708499 · Cited by 28
Li, D., Liu, Y., & Wang, B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233732 · Cited by 25
“Although antifibrotics, such as pirfenidone and nintedanib, have shown promising results in slowing disease progression [1, 2], it may bring potential serious side effects and help little for end-stage disease.”
BackgroundNoor, S., Nawaz, S., & Chaudhuri, N. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01523-7 · Cited by 26
Cardiovascular and Pulmonary Challenges After Treatment of Childhood Cancer
Visscher, H., Otth, M., Feijen, E. A. M., Nathan, P. C., & Kuehni, C. E. (2020) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2020.07.007 · Cited by 20
Chen, T., Tsai, A. P. Y., Hur, S. A., Wong, A. W., Sadatsafavi, M., Fisher, J. H., Johannson, K. A., Assayag, D., Morisset, J., Shapera, S., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01790-0 · Cited by 26
Self-citationEbrahimpour, A., Wang, M., Li, L., Jegga, A. G., Bonnen, M., Eissa, N. T., Raghu, G., Jyothula, S., Kheradmand, F., Hanania, N. A., et al. (2021) · Journal of Inflammation · doi:10.1186/s12950-021-00284-6 · Cited by 22
Self-citationIL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis
Nakanishi, Y., Horimasu, Y., Yamaguchi, K., Sakamoto, S., Masuda, T., Nakashima, T., Miyamoto, S., Iwamoto, H., Ohshimo, S., Fujitaka, K., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252594 · Cited by 22
Time-Dependent Molecular Motifs of Pulmonary Fibrogenesis in COVID-19
Kamp, J. C., Neubert, L., Ackermann, M., Stark, H., Werlein, C., Fuge, J., Haverich, A., Tzankov, A., Steinestel, K., Friemann, J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031583 · Cited by 21
Chronic Lung Allograft Dysfunction
Venado, A. E., Kukreja, J., & Greenland, J. R. (2022) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2021.11.004 · Cited by 23
Wu, W.-J., Huang, W., Liang, C.-H., & Yun, C. (2022) · BMC Medical Imaging · doi:10.1186/s12880-022-00803-8 · Cited by 26
Veerman, G., van der Werff, S. C., Koolen, S. L. W., Miedema, J., Hoop, E. O., van der Mark, S. C., Chandoesing, P. P., de Bruijn, P., Wijsenbeek, M. S., & Mathijssen, R. H. J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113101 · Cited by 24
The Effect of Nintedanib in Post-COVID-19 Lung Fibrosis: An Observational Study
Saiphoklang, N., Patanayindee, P., & Ruchiwit, P. (2022) · Critical Care Research and Practice · doi:10.1155/2022/9972846 · Cited by 30
Idiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols
Patel, H., Shah, J. R., Patel, D., Avanthika, C., Jhaveri, S., & Gor, K. (2022) · Disease-a-Month · doi:10.1016/j.disamonth.2022.101484 · Cited by 25
Anan, K., Kataoka, Y., Ichikado, K., Kawamura, K., Johkoh, T., Fujimoto, K., Tobino, K., Tachikawa, R., Ito, H., Nakamura, T., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02195-3 · Cited by 26
Behr, J., Bonella, F., Frye, B. C., Günther, A., Hagmeyer, L., Henes, J. C., Klemm, P., Koschel, D., Kreuter, M., Leuschner, G., et al. (2023) · Pneumologie · doi:10.1055/a-1983-6796 · Cited by 26
“Andere und insbesondere schwere unerwünschte Nebenwirkungen wurden in vergleichbarer Häufigkeit im Verum- wie im Placebo-Arm beobachtet [22].”
BackgroundInfluentialSelf-citationNam, J. G., Choi, Y., Lee, S., Yoon, S. H., Goo, J. M., & Kim, H. (2023) · European Radiology · doi:10.1007/s00330-023-09534-y · Cited by 23
Treatment strategies for idiopathic interstitial pneumonias
Wells, A. U., Kokosi, M. A., & Karagiannis, K. (2014) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000085 · Cited by 23
Lim, H.-J., Chung, M. J., Shin, K. E., Hwang, H. S., & Lee, K. S. (2016) · Korean Journal of Radiology · doi:10.3348/kjr.2016.17.6.950 · Cited by 22
Novel form of miR-29b suppresses bleomycin-induced pulmonary fibrosis
Yamada, Y., Takanashi, M., Sudo, K., Ueda, S., Ohno, S., & Kuroda, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171957 · Cited by 22
Time for an International Consensus on Hypersensitivity Pneumonitis. A Call to Arms
Molyneaux, P. L., & Maher, T. M. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201707-1439ed · Cited by 21
Chan, J. K., Deng, W., Higgins, R. V., Tewari, K. S., Bonebrake, A. J., Hicks, M. L., Gaillard, S. L., Ramirez, P. T., Chafe, W. E., Monk, B. J., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.05.033 · Cited by 23
Targeting the Myofibroblast in Pulmonary Fibrosis
Misharin, A. V., & Budinger, G. R. S. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201806-1037ed · Cited by 24
Ronan, N. J., Bennett, D. M., Khan, K. A., McCarthy, Y., Dahly, D. L., Bourke, L., Chelliah, A., Cavazza, A., O'Regan, K. N., Moloney, F., et al. (2018) · Lung · doi:10.1007/s00408-018-0140-8 · Cited by 22
Schrijver, B., Kooiman, M. A., Kasteleijn, E., van Holten-Neelen, C., Virakul, S., Paridaens, D. A., Peeters, R. P., van Hagen, P. M., Dalm, V. A. S. H., & Dik, W. A. (2019) · Thyroid · doi:10.1089/thy.2018.0544 · Cited by 25
Cocconcelli, E., Balestro, E., Biondini, D., Barbiero, G., Polverosi, R., Calabrese, F., Pezzuto, F., Lacedonia, D., Rea, F., Schiavon, M., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030399 · Cited by 24
“Due to the availability of effective anti-fibrotic drugs [30,31], studies on IPF patients naïve of antifibrotics will become progressively less common, if at all possible (and ethical).”
BackgroundSakayori, M., Terada, J., Abe, M., Hirasawa, Y., Suzuki, K., Yoshioka, K., Tsushima, K., & Tatsumi, K. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s208733 · Cited by 25
Zhang, T., Dai, J., Ye, W., Cai, L., Wei, J., Chen, M., Huang, X., & Wang, X. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.04.156 · Cited by 21
Calverley, B. C., Kadler, K. E., & Pickard, A. (2020) · Cells · doi:10.3390/cells9092070 · Cited by 21
Ground glass and fibrotic change in children with surfactant protein C dysfunction mutations
DeBoer, E. M., Liptzin, D. R., Humphries, S. M., Lynch, D. A., Robison, K., Galambos, C., Dishop, M. K., Deterding, R. R., & Weinman, J. P. (2021) · Pediatric Pulmonology · doi:10.1002/ppul.25356 · Cited by 22
NOX4 regulates macrophage apoptosis resistance to induce fibrotic progression
Larson‐Casey, J. L., Gu, L., Kang, J., Dhyani, A., & Carter, A. B. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100810 · Cited by 26
“Asbestosis subjects had to meet the following criteria: (1) FVC (forced vital capacity) at least 50% predicted; (2) current nonsmoker; (3) no recent or current evidence of infection; (4) evidence of restrictive physiology on pulmonary function tests; and (5) usual interstitial pneumonia on high-resolution chest comput…”
BackgroundNovedades diagnósticas y terapéuticas en fibrosis pulmonar progresiva
Molina‐Molina, M., Buendía-Roldán, I., Castillo, D., Caro, F. M., Valenzuela, C., & Selman, M. (2022) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2021.12.006 · Cited by 25
Self-citationMeta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
Bonella, F., Cottin, V., Valenzuela, C., Wijsenbeek, M. S., Voß, F., Rohr, K. B., Stowasser, S., & Maher, T. M. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02145-x · Cited by 21
Self-citationSoldano, S., Smith, V. M., Montagna, P., Gotelli, E., Campitiello, R., Pizzorni, C., Paolino, S., Sulli, A., Cere, A., & Cutolo, M. (2024) · Arthritis Research & Therapy · doi:10.1186/s13075-024-03308-7 · Cited by 23
Revisiting the role of MicroRNAs in the pathogenesis of idiopathic pulmonary fibrosis
Zhou, Z., Xie, Y., Wei, Q., Zhang, X., & Xu, Z. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1470875 · Cited by 23
Advances in idiopathic pulmonary fibrosis diagnosis and treatment
Liu, H., Shen, J., & He, C. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.02.001 · Cited by 23
Cordeiro, C. R., Campos, P., Carvalho, L., Borba, A., Clemente, S., Freitas, S., Furtado, S. T., Jesus, J. M., Leal, C., Marqués, J., et al. (2017) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2017.05.005 · Cited by 23
Niwa, H., Nakahara, Y., Yokoba, M., Mitsufuji, H., Sasaki, J., & Masuda, N. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1359 · Cited by 20
Characteristics and evaluation of acute exacerbations in chronic interstitial lung diseases
Kershaw, C. D., Batra, K., Torrealba, J. R., & Terada, L. S. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106400 · Cited by 26
Post‐translational regulation of PGC‐1α modulates fibrotic repair
Larson‐Casey, J. L., Gu, L., Davis, D., Cai, G., Ding, Q., He, C., & Carter, A. B. (2021) · The FASEB Journal · doi:10.1096/fj.202100339r · Cited by 24
Polke, M., Kondoh, Y., Wijsenbeek, M. S., Cottin, V., Walsh, S. L. F., Collard, H. R., Chaudhuri, N., Avdeev, S. N., Behr, J., Calligaro, G., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.699644 · Cited by 27
“The approach by physicians to utilise antifibrotic drugs as a form of preventive strategy is supported by recent data of controlled trials that suggest nintedanib may prolong the time to the first AE-IPF (31) and reduces mortality after AEIPF (32).”
ResultSelf-citationMiao, Y., Geng, Y., Yang, L., Zheng, Y., Dai, Y., & Wei, Z. (2021) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2021.108923 · Cited by 22
Li, S., Yang, Q., Chen, F., Tian, L., Huo, J., Meng, Y., Tang, Q., & Wang, W. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114901 · Cited by 20
Jalbert, A.-C., Siafa, L., Ramanakumar, A. V., & Assayag, D. (2022) · European Respiratory Journal · doi:10.1183/13993003.02969-2021 · Cited by 20
CRTH2 Mediates Profibrotic Macrophage Differentiation and Promotes Lung Fibrosis
Cao, Y., Rudrakshala, J., Williams, R., Rodriguez, S., Sorkhdini, P., Yang, A. X., Mundy, M. A., Yang, D., Palmisciano, A. J., Walsh, T. P., et al. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0504oc · Cited by 25
Chung, C., Kim, J., Cho, H. S., & Kim, H. C. (2022) · Scientific Reports · doi:10.1038/s41598-022-12399-8 · Cited by 27
Egea-Zorrilla, A., Vera, L., Sáez, B., & Pardo–Saganta, A. (2022) · Cells · doi:10.3390/cells11162595 · Cited by 22
Diagnosis and Treatment of Lung Cancer in the Setting of Interstitial Lung Disease
Fisher, D. A., Murphy, M. C., Montesi, S. B., Hariri, L. P., Hallowell, R. W., Keane, F. K., Lanuti, M. D., Mooradian, M. J., & Fintelmann, F. J. (2022) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2022.06.010 · Cited by 21
Therapeutic potential for P2Y2 receptor antagonism
Jasmer, K. J., Forti, K. M., Woods, L. T., Cha, S., & Weisman, G. A. (2022) · Purinergic Signalling · doi:10.1007/s11302-022-09900-3 · Cited by 23
Enomoto, N., Naoi, H., Mochizuka, Y., Isayama, T., Tanaka, Y., Fukada, A., Aono, Y., Katsumata, M., Yasui, H., Mori, K., et al. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02197-3 · Cited by 22
Lv, X., Liu, S., Liu, C., Li, Y., Zhang, T., Qi, J., Li, K., Hua, F., Cui, B., Zhang, X., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.008 · Cited by 22
“Acta Pharmaceutica Sinica B 2023;13(4):1631e1647”
Nakamura, Y., & Shimizu, Y. (2023) · Cells · doi:10.3390/cells12040548 · Cited by 22
“3%) were often seen as adverse reactions to NTD [68].”
BackgroundKoh, S. Y., Lee, J. H., Park, H., & Goo, J. M. (2023) · European Radiology · doi:10.1007/s00330-023-10483-9 · Cited by 24
SGLT-2 inhibitors as novel treatments of multiple organ fibrosis
Hu, J.-P., Teng, J., Hui, S., & Liang, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29486 · Cited by 26
“Despite advances in understanding fibrosis mechanisms and treatments, only a few therapies are available that marginally decelerate fibrosis progression [14,15].”
BackgroundShao, M., Qiu, Y., Shen, M., Liu, W. Q., Feng, D., Luo, Z., & Zhou, Y. (2024) · The FASEB Journal · doi:10.1096/fj.202302547rr · Cited by 27
Delineating, Imaging, and Assessing Pulmonary Fibrosis Remodeling via Collagen Hybridization
Zhao, J., Yu, W., Zhou, D., Liu, Y., Wei, J., Bi, L., Zhao, S., He, J., Liu, J., Su, J., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c06139 · Cited by 25
Wilson, K. C., & Raghu, G. (2015) · European Respiratory Journal · doi:10.1183/13993003.01335-2015 · Cited by 21
Self-citationKimman, M., Rotteveel, A. H., Wijsenbeek, M. S., Mostard, R. L. M., Tak, N. C., van Jaarsveld, X., Storm, M., Wijnsma, K. L., Gelens, M., van de Kar, N. C. A. J., et al. (2017) · Patient · doi:10.1007/s40271-017-0234-z · Cited by 22
Elinoff, J. M., Agarwal, R., Barnett, C. F., Benza, R. L., Cuttica, M. J., Gharib, A. M., Gray, M. P., Hassoun, P. M., Hemnes, A. R., Humbert, M. J. C., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201710-2093pp · Cited by 24
Unclassifiable interstitial lung disease: from phenotyping to possible treatments
Guler, S. A., & Ryerson, C. J. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000509 · Cited by 24
Attenuation of pulmonary fibrosis in type I collagen-targeted reporter mice with ALK-5 inhibitors
Terashima, H., Aonuma, M., Tsuchida, H., Sugimoto, K., Yokoyama, M., & Kato, M. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.11.005 · Cited by 20
Microenvironment-Responsive Small-Molecule Probe for Pulmonary Fibrosis Detection
Dong, Y., Li, X., Chen, Q., Guo, R., Tang, B., Kan, W., Zhang, W., Hu, Y., Li, J. X., Zang, Y., et al. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b02264 · Cited by 20
Occupational exposures and idiopathic pulmonary fibrosis
Walters, G. I. (2019) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000610 · Cited by 22
Rajasekar, N., Sivanantham, A., Kar, A. G., Mahapatra, S. K., Ahirwar, R., Thimmulappa, R. K., Paramasivam, S. G., & Rajasekaran, S. (2020) · Inflammopharmacology · doi:10.1007/s10787-020-00707-5 · Cited by 20
Kármán, J., Wang, J., Bodea, C. A., Cao, S., & Levesque, M. C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248889 · Cited by 28
“Currently, there are two FDA-approved therapies available for IPF patients, pirfenidone and nintedanib [3, 4].”
BackgroundChung, J. H., Adegunsoye, A., Cannon, B., Vij, R., Oldham, J. M., King, C. S., Montner, S. M., Thirkateh, P., Barnett, S. D., Karwoski, R. A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122663 · Cited by 24
Ma, Y., Zhou, R., & Wu, Q. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-1836 · Cited by 22
Iyoda, A., Azuma, Y., Sakamoto, S., Homma, S. A., & Sano, A. (2021) · Surgery Today · doi:10.1007/s00595-021-02343-0 · Cited by 22
Barone, S., Cassese, E., Alfano, A. I., Brindisi, M., & Summa, V. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02067 · Cited by 24
Guler, S. A., Clarenbach, C. F., Brutsche, M. H., Hostettler, K., Brill, A., Schertel, A., Geiser, T., & Funke-Chambour, M. (2021) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-211858 · Cited by 19
Meng, L., Zhang, X., Wang, H., Dong, H., Gu, X.-F., Yu, X., & Liu, Y. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/2710509 · Cited by 24
Antibody-based therapies for idiopathic pulmonary fibrosis
Sgalla, G., Flore, M., Siciliano, M., & Richeldi, L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1735346 · Cited by 22
“proved to be safe and effective therapeutic options [6,7] and were approved for use in patients with IPF by regulatory”
BackgroundSelf-citationSupplemental Oxygen Therapy in Interstitial Lung Disease: A Narrative Review
Clark, K. P., Degenholtz, H. B., Lindell, K. O., & Kass, D. J. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202304-391cme · Cited by 23
Isshiki, T., Sakamoto, S., Yamasaki, A., Shimizu, H., Miyoshi, S., Nakamura, Y., Homma, S., & Kishi, K. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106551 · Cited by 19
Pyruvate metabolism dictates fibroblast sensitivity to GLS1 inhibition during fibrogenesis
Contento, G., Wilson, J.-A. A. M., Selvarajah, B., Platé, M., Guillotin, D., Morales, V., Trevisani, M., Pitozzi, V., Bianchi, K., & Chambers, R. C. (2024) · JCI Insight · doi:10.1172/jci.insight.178453 · Cited by 23
Diagnosis of early idiopathic pulmonary fibrosis: current status and future perspective
Wang, X., Xu, X., Hou, Y., Zhang, H., Han, W., Sun, J., & Li, F. (2025) · Respiratory Research · doi:10.1186/s12931-025-03270-1 · Cited by 21
Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis
Yasuoka, H. (2015) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s23315 · Cited by 19
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.